We read with great interest the article by Grimm et al. comparing morbidity following open (OPN) versus robot-assisted partial nephrectomy (RAPN) for patients diagnosed with a complex kidney tumor. The authors should be congratulated on conducting a unique randomized clinical trial in the special setting of nephron-sparing surgery for anatomically complex renal masses that teaches several important lessons.1
The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning
Annals of Oncology | | A. Larcher, F. Cei, A. Mottrie, A. Salonia, U. Capitanio, F. Montorsi
Topics: blood-cancer, kidney-cancer, clinical-trials